UK Health Security Agency

The UK Health Security Agency, formerly doing business as Public Health England, is a government agency responsible for protecting public health in the United Kingdom. It provides a range of goods and services to the U.S. federal government, primarily through contracts and grants related to biomedical research, disease surveillance, and medical countermeasure development.

UK Health Security Agency has been awarded several prime and subcontract awards from U.S. federal agencies for biomedical research and development services. Notable prime contracts include a $5.5 million delivery order from the Department of Health and Human Services (HHS) for biological animal model and medical countermeasure development to combat chemical, biological, radiological, and nuclear threats. It also received a $12,000 contract from HHS for program management support activities related to advanced medical countermeasure development. UK Health Security Agency has partnered with organizations like Seattle Children's Hospital and Harvard University on subcontracts involving tuberculosis vaccine research, non-human primate models for COVID-19 therapies, and assay development. These contracts did not utilize any set-aside designations.

Through federal grant funding, UK Health Security Agency has conducted projects such as an ecological and epidemiological investigation of Crimean-Congo hemorrhagic fever virus in Azerbaijan, funded by a $648,000 grant from the Defense Threat Reduction Agency under the Combating Weapons of Mass Destruction program. It has also received sub-awards from grantees like Columbia University for genomic sequencing and biomarker development related to radiation exposure.

UK Health Security Agency holds a $100 million single-award indefinite delivery contract with the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to provide nonclinical services supporting the Biomedical Advanced Research and Development Authority's development of medical countermeasures against chemical, biological, radiological, and nuclear threats. Task orders issued to date total over $18 million for biological animal model development, medical countermeasure development, and contract management support services, with a period of performance through September 2027.